

Esperion Therapeutics, Inc. Investor Relations Department 3891 Ranchero Drive Suite 150 Ann Arbor, MI 48108 United States

Visit IR website ☐ Sign-up for Email alerts ☐ ☐


NASDAQ: ESPR	
Last Trade:	44.34
Trade Time:	4:00 PM ET Jun 23, 2017
Change:	2.03 🕇 (+4.798%)
Day Range	41.43 - 44.54
52-Week Range	9.40 - 48.21
Volume	1,174,636

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## **Company Profile**

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, nonstatin, once-daily, oral therapies to lower elevated low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipidmodifying therapies. Bempedoic acid, a convenient, complementary, costeffective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is "patient-friendly, physician-frie... (more)

## **Stock Performance**



## Press Releases [View all]

Jun 14, 2017

Esperion to Present at the JMP Securities 2017 Life Sciences Conference

May 31, 2017

Esperion to Present at the Jefferies 2017 Global Healthcare Conference

May 22, 2017

<u>Esperion Provides Update on Common Stock</u> <u>Trading Activity</u>

May 19, 2017

Esperion to Participate in Fireside Chat at the UBS Global Healthcare Conference

May 18, 2017

Esperion Announces Inducement Grants
Under NASDAQ Listing Rule 5635(c)(4)

## Financials [View all]

First Quarter Financial Results

Feb 22, 2017

Annual Report (10-K)

Mar 6, 2017

Proxy Statement (DEF 14A)

May 4, 2017

Quarterly Report (10-Q)

Nov 3, 2016

Quarterly Report (10-Q)

Aug 4, 2016

Quarterly Report (10-Q)